Would you add durvalumab to gem+cis in a patient with recurrent cholangiocarcinoma after liver transplant?
How would you balance the OS benefit from TOPAZ-1 with the risks of immunotherapy in this or other high-risk populations?
Community PollStarted
Are there specific patient types in whom you would avoid adding durvalumab to gem/cis in advanced BTC?
36 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Answered on
I would not offer gemcitabine/cisplatin plus durvalumab to a patient with recurrent cholangiocarcinoma after a liver transplant. The added clinical benefit of durvalumab is modest, and the risk of a life threatening liver transplant rejection is high.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Johns Hopkins University
Answered on
At this point, I would not without safety data abut losing the transplant data.
Join for free or sign in to see the full answer